Equity (Details Narrative) - USD ($) |
9 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|
Aug. 05, 2021 |
May 18, 2021 |
Apr. 16, 2021 |
Feb. 11, 2021 |
Sep. 30, 2021 |
Jun. 30, 2021 |
Dec. 31, 2020 |
Mar. 24, 2020 |
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
| Preferred Stock, No Par Value | $ 0 | $ 0 | $ 0.01 | |||||
| Preferred stock conversion price | $ 0.01 | |||||||
| Preferred stock terms of conversion | A holder of Preferred Stock will be prohibited from converting Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding (with such ownership restriction referred to as the “Beneficial Ownership Limitation”). However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to us. | |||||||
| Merger agreement, description | Among other things, the A&R Charter (i) changed the Company’s name to MyMD Pharmaceuticals, Inc., (ii) increased the number of shares of Company Common Stock available from 100,000,000 shares to a total of 500,000,000 shares of the Company’s Common Stock, (iii) changed the structure of the board of directors from a classified board of three classes to a non-classified board of a single class, and (iv) simplified and consolidated various provisions. | |||||||
| Warrants exercised | 466,216 | |||||||
| Stock issued during the period | 16,826 | 466,716 | ||||||
| Fair market value | $ 90,002 | |||||||
| Warrant exercise price | $ 47,298 | |||||||
| Proceeds from Issuance of Warrants | $ 194,868 | |||||||
| Common Stock Warrants [Member] | ||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
| Warrant exercise price | $ 7.20 | $ 7.20 | ||||||
| Warrants outstanding | 5,316,249 | |||||||
| Pre-funded Common Stock Warrants [Member] | ||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
| Warrant exercise price | $ 7.20 | |||||||
| Warrants outstanding | 520,270 | |||||||
| Series C Convertible Preferred Stock [Member] | ||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
| Warrant exercise price | $ 7.20 | |||||||
| Warrants outstanding | 27,500 | |||||||
| Securities Purchase Agreement [Member] | ||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
| Conversion of Stock, Shares Converted | 466,216 | |||||||
| Securities Purchase Agreement [Member] | Pre-funded Warrants [Member] | ||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||
| Debt Conversion, Converted Instrument, Warrants or Options Issued | 466,216 |